Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares saw strong trading volume on Tuesday . 124,977 shares changed hands during trading, an increase of 7% from the previous session's volume of 116,958 shares.The stock last traded at $8.39 and had previously closed at $7.68.
Wall Street Analyst Weigh In
Separately, Noble Financial assumed coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating on the stock.
Get Our Latest Stock Report on GYRE
Gyre Therapeutics Stock Performance
The firm has a market capitalization of $747.25 million, a price-to-earnings ratio of 398.50 and a beta of 1.90. The business has a fifty day moving average of $8.91 and a two-hundred day moving average of $10.40.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.03 earnings per share for the quarter, hitting analysts' consensus estimates of $0.03. The business had revenue of $22.06 million for the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in shares of Gyre Therapeutics by 15,083.3% during the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock worth $140,000 after acquiring an additional 1,810 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares in the last quarter. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock valued at $84,000 after buying an additional 1,996 shares in the last quarter. Barclays PLC grew its holdings in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after buying an additional 1,255 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP grew its holdings in Gyre Therapeutics by 54.0% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock valued at $105,000 after buying an additional 4,790 shares in the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
